Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August

OMEROS CORP

2022-Q2 EPS reported -$1.02

Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.
Net loss $30.9M ($0.49/share) vs $28.6M ($0.46/share) in Q2 2021.
Cash and short-term investments $122.6M as of June 30, down $19.7M from Q1.
Submitted Formal Dispute Resolution to FDA for narsoplimab in TA-TMA; decision expected in August 2022.
OMS906 received orphan drug designation for PNH; Phase 1b trials expanding to treatment-naïve and C3G patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.